Essential Thrombocythemia and Cardiac Surgery

A Case Series and Review of the Literature

Carmelina Gurrieri, Bradford B. Smith, Gregory A. Nuttall, Rajiv K. Pruthi, Sameh M. Said, Mark M. Smith

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Essential thrombocythemia (ET) is a rare myeloproliferative disorder characterized by an unexplained thrombocytosis (>450 × 109/L) and associated vasomotor, thrombotic, and hemorrhagic manifestations. Although the literature detailing the perioperative management of patients with ET undergoing cardiac operations is sparse, major perioperative complications have been reported, particularly in poorly controlled patients presenting with platelet counts of 800 × 109/L or higher. The purpose of this study was to provide the experience at a large tertiary medical center in managing patients with ET undergoing cardiac operation and to summarize the available literature. Methods: Patients with ET undergoing cardiac operations between January 1, 2006, and May 1, 2016, were identified. Perioperative data were exhaustively reviewed and recorded. An extensive literature search for “essential thrombocythemia” and “cardiac surgery” was performed. Results: During the study period, 25 patients with ET underwent cardiac operations, and 24 had immediate preoperative platelet counts of less than 800 × 109/L. Perioperative complications related to ET occurred in 1 of 25 patients (4%). The immediate preoperative platelet count was 181 × 109/L. A literature search identified 18 patients who underwent cardiac operations, with major perioperative complications occurring in 5 (28%), of which 4 of 5 had an immediate preoperative platelet count of 800 × 109/L or higher. Conclusions: Patients with ET undergoing cardiac operations represent a complex cohort at risk for perioperative thrombotic or hemorrhagic complications, or both. Although not currently an indication for platelet reduction therapy by risk stratification criteria, preoperative cytoreduction to platelet counts of less than 800 × 109/L and perhaps lower should be considered in patients undergoing cardiac operations.

Original languageEnglish (US)
Pages (from-to)482-490
Number of pages9
JournalAnnals of Thoracic Surgery
Volume106
Issue number2
DOIs
StatePublished - Aug 1 2018

Fingerprint

Essential Thrombocythemia
Thoracic Surgery
Platelet Count
Thrombocytosis
Myeloproliferative Disorders
Risk Reduction Behavior
Blood Platelets

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Gurrieri, C., Smith, B. B., Nuttall, G. A., Pruthi, R. K., Said, S. M., & Smith, M. M. (2018). Essential Thrombocythemia and Cardiac Surgery: A Case Series and Review of the Literature. Annals of Thoracic Surgery, 106(2), 482-490. https://doi.org/10.1016/j.athoracsur.2018.03.057

Essential Thrombocythemia and Cardiac Surgery : A Case Series and Review of the Literature. / Gurrieri, Carmelina; Smith, Bradford B.; Nuttall, Gregory A.; Pruthi, Rajiv K.; Said, Sameh M.; Smith, Mark M.

In: Annals of Thoracic Surgery, Vol. 106, No. 2, 01.08.2018, p. 482-490.

Research output: Contribution to journalArticle

Gurrieri, C, Smith, BB, Nuttall, GA, Pruthi, RK, Said, SM & Smith, MM 2018, 'Essential Thrombocythemia and Cardiac Surgery: A Case Series and Review of the Literature', Annals of Thoracic Surgery, vol. 106, no. 2, pp. 482-490. https://doi.org/10.1016/j.athoracsur.2018.03.057
Gurrieri, Carmelina ; Smith, Bradford B. ; Nuttall, Gregory A. ; Pruthi, Rajiv K. ; Said, Sameh M. ; Smith, Mark M. / Essential Thrombocythemia and Cardiac Surgery : A Case Series and Review of the Literature. In: Annals of Thoracic Surgery. 2018 ; Vol. 106, No. 2. pp. 482-490.
@article{c6487131e5354dc69e5d08c40f4e52da,
title = "Essential Thrombocythemia and Cardiac Surgery: A Case Series and Review of the Literature",
abstract = "Background: Essential thrombocythemia (ET) is a rare myeloproliferative disorder characterized by an unexplained thrombocytosis (>450 × 109/L) and associated vasomotor, thrombotic, and hemorrhagic manifestations. Although the literature detailing the perioperative management of patients with ET undergoing cardiac operations is sparse, major perioperative complications have been reported, particularly in poorly controlled patients presenting with platelet counts of 800 × 109/L or higher. The purpose of this study was to provide the experience at a large tertiary medical center in managing patients with ET undergoing cardiac operation and to summarize the available literature. Methods: Patients with ET undergoing cardiac operations between January 1, 2006, and May 1, 2016, were identified. Perioperative data were exhaustively reviewed and recorded. An extensive literature search for “essential thrombocythemia” and “cardiac surgery” was performed. Results: During the study period, 25 patients with ET underwent cardiac operations, and 24 had immediate preoperative platelet counts of less than 800 × 109/L. Perioperative complications related to ET occurred in 1 of 25 patients (4{\%}). The immediate preoperative platelet count was 181 × 109/L. A literature search identified 18 patients who underwent cardiac operations, with major perioperative complications occurring in 5 (28{\%}), of which 4 of 5 had an immediate preoperative platelet count of 800 × 109/L or higher. Conclusions: Patients with ET undergoing cardiac operations represent a complex cohort at risk for perioperative thrombotic or hemorrhagic complications, or both. Although not currently an indication for platelet reduction therapy by risk stratification criteria, preoperative cytoreduction to platelet counts of less than 800 × 109/L and perhaps lower should be considered in patients undergoing cardiac operations.",
author = "Carmelina Gurrieri and Smith, {Bradford B.} and Nuttall, {Gregory A.} and Pruthi, {Rajiv K.} and Said, {Sameh M.} and Smith, {Mark M.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.athoracsur.2018.03.057",
language = "English (US)",
volume = "106",
pages = "482--490",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Essential Thrombocythemia and Cardiac Surgery

T2 - A Case Series and Review of the Literature

AU - Gurrieri, Carmelina

AU - Smith, Bradford B.

AU - Nuttall, Gregory A.

AU - Pruthi, Rajiv K.

AU - Said, Sameh M.

AU - Smith, Mark M.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Essential thrombocythemia (ET) is a rare myeloproliferative disorder characterized by an unexplained thrombocytosis (>450 × 109/L) and associated vasomotor, thrombotic, and hemorrhagic manifestations. Although the literature detailing the perioperative management of patients with ET undergoing cardiac operations is sparse, major perioperative complications have been reported, particularly in poorly controlled patients presenting with platelet counts of 800 × 109/L or higher. The purpose of this study was to provide the experience at a large tertiary medical center in managing patients with ET undergoing cardiac operation and to summarize the available literature. Methods: Patients with ET undergoing cardiac operations between January 1, 2006, and May 1, 2016, were identified. Perioperative data were exhaustively reviewed and recorded. An extensive literature search for “essential thrombocythemia” and “cardiac surgery” was performed. Results: During the study period, 25 patients with ET underwent cardiac operations, and 24 had immediate preoperative platelet counts of less than 800 × 109/L. Perioperative complications related to ET occurred in 1 of 25 patients (4%). The immediate preoperative platelet count was 181 × 109/L. A literature search identified 18 patients who underwent cardiac operations, with major perioperative complications occurring in 5 (28%), of which 4 of 5 had an immediate preoperative platelet count of 800 × 109/L or higher. Conclusions: Patients with ET undergoing cardiac operations represent a complex cohort at risk for perioperative thrombotic or hemorrhagic complications, or both. Although not currently an indication for platelet reduction therapy by risk stratification criteria, preoperative cytoreduction to platelet counts of less than 800 × 109/L and perhaps lower should be considered in patients undergoing cardiac operations.

AB - Background: Essential thrombocythemia (ET) is a rare myeloproliferative disorder characterized by an unexplained thrombocytosis (>450 × 109/L) and associated vasomotor, thrombotic, and hemorrhagic manifestations. Although the literature detailing the perioperative management of patients with ET undergoing cardiac operations is sparse, major perioperative complications have been reported, particularly in poorly controlled patients presenting with platelet counts of 800 × 109/L or higher. The purpose of this study was to provide the experience at a large tertiary medical center in managing patients with ET undergoing cardiac operation and to summarize the available literature. Methods: Patients with ET undergoing cardiac operations between January 1, 2006, and May 1, 2016, were identified. Perioperative data were exhaustively reviewed and recorded. An extensive literature search for “essential thrombocythemia” and “cardiac surgery” was performed. Results: During the study period, 25 patients with ET underwent cardiac operations, and 24 had immediate preoperative platelet counts of less than 800 × 109/L. Perioperative complications related to ET occurred in 1 of 25 patients (4%). The immediate preoperative platelet count was 181 × 109/L. A literature search identified 18 patients who underwent cardiac operations, with major perioperative complications occurring in 5 (28%), of which 4 of 5 had an immediate preoperative platelet count of 800 × 109/L or higher. Conclusions: Patients with ET undergoing cardiac operations represent a complex cohort at risk for perioperative thrombotic or hemorrhagic complications, or both. Although not currently an indication for platelet reduction therapy by risk stratification criteria, preoperative cytoreduction to platelet counts of less than 800 × 109/L and perhaps lower should be considered in patients undergoing cardiac operations.

UR - http://www.scopus.com/inward/record.url?scp=85050154325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050154325&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2018.03.057

DO - 10.1016/j.athoracsur.2018.03.057

M3 - Article

VL - 106

SP - 482

EP - 490

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -